Scrying Biotech
Long only, biotech, micro-cap, small-cap

A Nektar Victory

It's good to be in Nektar (NKTR) today. I followed my own advice and removed half of my position in Nektar prior to the OIC advisory committee meeting, and I'm glad I did. I didn't worry at all during the two day event, and found myself a winner following a more than favorable outcome. I'll now wait patiently for a reentry point to be executed after this initial exuberance has subsided.

Looking Ahead

It's also good to anticipate what's next for Nektar. Take a look at my revised catalyst calendar for the balance of this year. We'll laser focus on the meaning behind each of these events and by doing so, see that Nektar's metamorphosis into a mid-cap...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details